GET DAILY SIGNALSRigel Pharmaceuticals (RIGL) Delivers Solid Q3 Results as VEPPANU Enters the Market
Key Takeaways
- Total revenue reached $80.9 million in the third quarter of 2026, including net product sales of $72.3 million and $8.6 million in collaboration revenue.
- The newly launched breast cancer therapy VEPPANU (vepdegestrant) generated $6.6 million in net product sales across roughly six weeks of commercial availability.
- TAVALISSE contributed $46.0 million (up 3% year over year), REZLIDHIA added $9.9 million (up 20%), while GAVRETO declined 11% to $9.8 million.
- Net income was $39.1 million, or $1.97 per diluted share, down from $99.0 million a year earlier, a period that included $40.0 million in non-cash Lilly collaboration revenue.
- Rigel raised its full-year 2026 total revenue guidance to approximately $290 million to $295 million, excluding VEPPANU.
Why This Quarter Matters for Rigel
Rigel Pharmaceuticals, a commercial-stage biotech focused on hematologic disorders and cancer, entered its third quarter of 2026 at a pivotal moment. The mid-August launch of VEPPANU—the first U.S. Food and Drug Administration (FDA)-approved PROTAC (proteolysis targeting chimera) for ESR1-mutated metastatic breast cancer—gave the company its first commercial entry into oncology's large breast cancer market. This report offered investors their first real look at early VEPPANU adoption while testing whether the established TAVALISSE, REZLIDHIA, and GAVRETO franchises could sustain momentum. The quarter also carries a difficult year-over-year comparison, as the prior-year period included a one-time $40.0 million non-cash benefit tied to the Lilly collaboration. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Show
For the third quarter ended September 30, 2026, Rigel reported total revenue of $80.9 million, consisting of $72.3 million in net product sales and $8.6 million in contract revenue from collaborations. Net product sales rose 13% from the prior-year quarter's $64.1 million.
VEPPANU, launched in mid-August, delivered $6.6 million in net product sales during roughly six weeks of availability, with management citing rapid geographic adoption and strong commercial and Medicare prior-authorization approval rates. TAVALISSE generated $46.0 million, up 3% year over year, while REZLIDHIA grew 20% to $9.9 million. GAVRETO declined 11% to $9.8 million.
Net income came in at $39.1 million, or $1.97 per diluted share, compared with $99.0 million, or $5.38 per diluted share, in the same period of 2025. The prior-year result included $40.0 million in non-cash revenue related to the company's Lilly collaboration, which skews the comparison. Income before income taxes was $52.7 million, versus $99.1 million a year ago.
Rigel also raised its 2026 outlook. Total revenue guidance moved to approximately $290 million to $295 million, with net product sales of $255 million to $260 million and contract revenue of roughly $35 million. The guidance excludes VEPPANU. The company reaffirmed its expectation of positive full-year net income.
How Investors Reacted
Following the release, Rigel shares edged lower in after-hours trading, reflecting a muted initial response to the results. While the VEPPANU launch and raised guidance were clear positives, investors weighed the steep year-over-year decline in net income—largely attributable to the prior-year's non-cash Lilly revenue—alongside a narrowing of net product sales guidance. The exclusion of VEPPANU from full-year guidance also left some questions about the timing and scale of the launch's contribution. Sentiment remains balanced between enthusiasm for the new oncology franchise and caution around the durability of profitability across the broader commercial portfolio.
What to Watch Going Forward
Investors will focus next on the pace of VEPPANU adoption. Management has indicated it will stop providing detailed launch metrics and report VEPPANU within net product sales going forward, so quarterly sales growth and gross-to-net trends will become key signals of the drug's trajectory in the ESR1-mutated metastatic breast cancer market.
On the pipeline front, updated data from the Phase 1b study of R289, a dual IRAK1/4 (interleukin receptor-associated kinases 1 and 4) inhibitor, in lower-risk myelodysplastic syndromes (MDS) is expected to be presented at a major medical meeting in December. This readout could shape expectations for the program's next clinical steps and competitive positioning.
Financially, Rigel ended the quarter with $99.3 million in cash, cash equivalents, and short-term investments, down from $155.0 million at the end of 2025. How management balances spending on the VEPPANU launch and R289 development against its commitment to full-year profitability will be a central theme in the quarters ahead. The company's reiterated target of positive net income for 2026—while funding both commercial and clinical initiatives—remains the key figure to watch. From what I see, this balance will be important to monitor closely.
Exploring AI Tools for Biotech Analysis
In my own research, I often turn to Tickeron’s AI Screener when evaluating earnings reports like this one. It allows quick filtering by industry, fundamentals, and technical signals, which helps compare Rigel’s performance against peers in the biotech space without spending hours on manual screens. This kind of tool fits well into a routine review of commercial-stage companies navigating new product launches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RIGL saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for RIGL moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 59 similar instances where the indicator exited the overbought zone. In 49 of the 59 cases the stock moved lower. This puts the odds of a downward move at 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RIGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on RIGL as a result. In 59 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for RIGL just turned positive on October 26, 2026. Looking at past instances where RIGL's MACD turned positive, the stock continued to rise in 27 of 36 cases over the following month. The odds of a continued upward trend are 75%.
RIGL moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where RIGL advanced for three days, in 226 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 173 of 210 cases where RIGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RIGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.007) is normal, around the industry mean (2.904). P/E Ratio (2.565) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage drug development company that discovers and develops novel, small-molecule drugs
Industry Biotechnology
Advertisement